Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 2c
Tweet Send to a FriendGet Alerts HALO Hot Sheet
Price: $7.20 -5.14%
EPS Growth %: -21.4%
Financial Fact:
Revenues under collaborative agreements: 10.32M
Today's EPS Names:
DSX, REDF, REX, More
EPS Growth %: -21.4%
Financial Fact:
Revenues under collaborative agreements: 10.32M
Today's EPS Names:
DSX, REDF, REX, More
Trade HALO Now!
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.63 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- Booz Allen Hamilton (BAH) Tops Q4 EPS by 3c; Guides In-Line FY14 EPS
- American Eagle Outfitters, Inc. (AEO) Tops Q1 EPS by 1c; Issues Weak EPS Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
